Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review
Y Zhu, L Sharma, D Chang - Frontiers in Immunology, 2023 - frontiersin.org
An unprecedented global pandemic caused by a novel coronavirus named SARS-CoV-2
has created a severe healthcare threat and become one of the biggest challenges to human …
has created a severe healthcare threat and become one of the biggest challenges to human …
Immunogenicity and safety of homologous and heterologous prime–boost immunization with COVID-19 vaccine: systematic review and meta-analysis
H Cheng, Z Peng, S Si, X Alifu, H Zhou, P Chi… - Vaccines, 2022 - mdpi.com
A prime–boost strategy of COVID-19 vaccines brings hope to limit the spread of SARS-CoV-
2, while the immunogenicity of the vaccines is waning over time. Whether a booster dose of …
2, while the immunogenicity of the vaccines is waning over time. Whether a booster dose of …
Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older …
EK Alidjinou, J Demaret, B Corroyer-Simovic… - The Lancet Regional …, 2022 - thelancet.com
Background The present study aimed to evaluate the persistent immunogenicity offered by a
third dose of BNT162b2 against Delta and Omicron variants, in nursing home (NH) …
third dose of BNT162b2 against Delta and Omicron variants, in nursing home (NH) …
Strong decay of SARS-CoV-2 spike antibodies after 2 BNT162b2 vaccine doses and high antibody response to a third dose in nursing home residents
H Blain, E Tuaillon, L Gamon, A Pisoni, S Miot… - Journal of the American …, 2022 - Elsevier
Objectives To measure the antibody decay after 2 BNT162b2 doses and the antibody
response after a third vaccine dose administered 6 months after the second one in nursing …
response after a third vaccine dose administered 6 months after the second one in nursing …
[HTML][HTML] Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple …
HM Bajwa, F Novak, AC Nilsson, C Nielsen… - Multiple sclerosis and …, 2022 - Elsevier
Objective To examine humoral and cellular response in multiple sclerosis patients on anti-
CD20 therapy after third BNT162b2 mRNA SARS-CoV-2 vaccination. Methods A …
CD20 therapy after third BNT162b2 mRNA SARS-CoV-2 vaccination. Methods A …
Pronounced antibody elevation after SARS‐CoV‐2 BNT162b2 mRNA booster vaccination in nursing home residents
Y Chong, T Goto, N Tani, A Yonekawa… - Influenza and Other …, 2022 - Wiley Online Library
Background Infection control during COVID‐19 outbreaks in nursing facilities is a critical
public health issue. Antibody responses before and after the third (booster) dose of SARS …
public health issue. Antibody responses before and after the third (booster) dose of SARS …
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine …
Background Our study investigated the rate of breakthrough SARS-CoV-2 infection and
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
[HTML][HTML] Omicron variant: A clear and present danger for patients with cancer
J Barrière, G Zalcman, L Fignon… - European Journal of …, 2022 - ncbi.nlm.nih.gov
Protection of patients with cancer against SARS-CoV-2 infection has been a priority for
oncologists since early 2020. Recently, we have recommended to prioritise patients under …
oncologists since early 2020. Recently, we have recommended to prioritise patients under …
Managing the impact of COVID-19 in nursing homes and long-term care facilities: an update
Older adults in nursing homes are at greatest risk of morbidity and mortality from SARS-CoV-
2 infection. Nursing home residents constituted one-third to more than half of all deaths …
2 infection. Nursing home residents constituted one-third to more than half of all deaths …
[HTML][HTML] Follow-up of SARS-CoV-2 antibody levels in Belgian nursing home residents and staff two, four and six months after primary course BNT162b2 vaccination
E Meyers, L De Rop, F Engels, C Gioveni, A Coen… - Vaccines, 2024 - mdpi.com
When COVID-19 vaccines were implemented, nursing home residents (NHRs) and staff
(NHS) in Belgium were prioritized for vaccination. To characterize the vaccine response over …
(NHS) in Belgium were prioritized for vaccination. To characterize the vaccine response over …